https://orcid.org/0000-0001-9070-4383
References
- Network NCC Anal carcinoma. [cited 2019 Nov 18]. Available from: https://www.nccn.org
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
- Rogers JE, Eng C. Pharmacotherapy of anal cancer. Drugs. 2017;77(14):1519–1530.
- Prevention, C.f.D.C.a. More US adolescents up to date on HPV vaccination. [cited 2019 Jun 4]. Available from: https://www.cdc.gov/media/releases/2018/p0823-HPV-vaccination.html
- Institute NC Surveillance, epidemiology, and end results program. Cancer stat facts: anal cancer. [cited 2019 Jun 4]. Available from: https://seer.cancer.gov/statfacts/html/anus.html
- Rao S, Sclafani F, Eng C, et al. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - an international rare cancers initiative (IRCI) trial. Ann Oncol. 2018;29:viii715–viii716.
- Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446–453.
- Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28(5):1036–1041.
- Casadei Gardini A, Passardi A, Fornaro L, et al. Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. Crit Rev Oncol Hematol. 2018;123:52–56.
- Morris V, Rao X, Pickering C, et al. Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal. Mol Cancer Res. 2017;15(11):1542–1550.
- Rogers JE, Ohinata A, Silva NN, et al. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs. 2016;27(8):804–808.
- Kim DW, Byer J, Kothari N, et al. EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience. Oncology. 2017;92(4):190–196.
- Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–1531.
- Rivera F, García-Castaño A, Vega N, et al. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009;9(10):1421–1428.
- Diagnosis, N.C.I.D.o.C.T.a. Common terminology criteria for adverse events (CTCAE) version 4. [cited 2019 Jun 4]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
- Adams CB, Street DS, Crass M, et al. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: an Appalachian effect? J Oncol Pharm Pract. 2016;22(6):784–789.
- Clinicaltrials.gov. Cetuximab + avelumab or avelumab alone for unresectable, locally advanced, or metastatic squamous cell anal carcinoma (SCCAC) progressed after at least one line of systemic treatment (CARACAS) NCT03944252. [cited 2019 Jun 4]. Available from: www.clinicaltrials.gov
- Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10(6):910–923.
- Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443.
- Saba NF, Chen ZG, Haigentz M, et al. Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance. Mol Cancer Ther. 2019;18(11):1909–1915.
- Velez MA, Burns TF. Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? Transl Lung Cancer Res. 2019;8(S4):S339–S342.